| P50 | author | Anna Kula-Pacurar | Q95605915 |
| | Stéphane De Wit | Q47006685 |
| | Gilles Darcis | Q47143122 |
| P2093 | author name string | Alessandro Marcello | |
| | Olivier Rohr | |
| | Carine Van Lint | |
| | Patrick W G Mallon | |
| | Roxane Verdikt | |
| | Amina Ait-Ammar | |
| | Virginie Gautier | |
| P2860 | cites work | Genetic Evidence That Naive T Cells Can Contribute Significantly to the Human Immunodeficiency Virus Intact Reservoir: Time to Re-evaluate Their Role | Q91819323 |
| | Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs | Q92300043 |
| | Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines | Q92344530 |
| | A CRISPR/Cas9 screen identifies the histone demethylase MINA53 as a novel HIV-1 latency-promoting gene (LPG) | Q92532794 |
| | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab | Q92668726 |
| | HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy | Q92689699 |
| | Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations | Q92697820 |
| | HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs | Q93020860 |
| | HIV Silencing and Inducibility Are Heterogeneous and Are Affected by Factors Intrinsic to the Virus | Q93023822 |
| | CD32 expressing doublets in HIV-infected gut-associated lymphoid tissue are associated with a T follicular helper cell phenotype | Q93025028 |
| | A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b | Q93129465 |
| | Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing | Q24294385 |
| | Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter | Q24634457 |
| | Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells | Q24679559 |
| | Redefining the viral reservoirs that prevent HIV-1 eradication | Q26827255 |
| | Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes | Q27324527 |
| | Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection | Q27331323 |
| | Are T cells the only HIV-1 reservoir? | Q28078850 |
| | 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes | Q28116607 |
| | NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation | Q28141291 |
| | The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription | Q28206012 |
| | A human memory T cell subset with stem cell-like properties | Q28248395 |
| | A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA | Q28263974 |
| | Epigenetic regulation of HIV-1 latency by cytosine methylation | Q28475636 |
| | Deep molecular characterization of HIV-1 dynamics under suppressive HAART | Q28477677 |
| | An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients | Q28538015 |
| | Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy | Q28544949 |
| | Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation | Q28546901 |
| | An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression | Q28546918 |
| | HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency | Q28646762 |
| | Analysis of HIV quasispecies suggests compartmentalization in the liver | Q42266226 |
| | In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a "Block-and-Lock" Strategy for HIV-1 Treatment. | Q42381408 |
| | CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency | Q42573954 |
| | c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter | Q42638819 |
| | Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). | Q42691966 |
| | Differential expression of CD45RO (UCHL1) and its functional relevance in two subpopulations of circulating TCR-gamma/delta+ lymphocytes | Q42937731 |
| | Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. | Q43226911 |
| | Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. | Q43792135 |
| | Both CD31(+) and CD31⁻ naive CD4(+) T cells are persistent HIV type 1-infected reservoirs in individuals receiving antiretroviral therapy | Q43941310 |
| | Comparison of HIV-1 pol and env sequences of blood, CSF, brain and spleen isolates collected ante-mortem and post-mortem | Q44740845 |
| | Negative regulation of HIV-1 transcription by a heterodimeric NF-κB1/p50 and C-terminally truncated STAT5 complex | Q44807679 |
| | Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates | Q44813168 |
| | HIV-1 pre-mRNA commitment to Rev mediated export through PSF and Matrin 3. | Q45372623 |
| | Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). | Q45395687 |
| | Genetic differences between human immunodeficiency virus type 1 subpopulations in faeces and serum | Q45757845 |
| | Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants. | Q46281767 |
| | The Spleen Is an HIV-1 Sanctuary During Combined Antiretroviral Therapy | Q46584933 |
| | Unique monocyte subset in patients with AIDS dementia | Q46631395 |
| | BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency | Q47120827 |
| | Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation | Q47201695 |
| | Integrin α4β7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes. | Q47549153 |
| | Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection. | Q47551736 |
| | PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy? | Q47551808 |
| | A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for re-activation from other 'shock' drugs | Q47552249 |
| | Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV. | Q47555333 |
| | Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. | Q47583584 |
| | CTLA-4+PD-1- Memory CD4+ T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques | Q47608280 |
| | HIV-1 infection of monocytes is directly related to the success of HAART. | Q48078114 |
| | Blood CXCR3+ CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals | Q49829305 |
| | HIV latency is reversed by ACSS2-driven histone crotonylation | Q49851068 |
| | Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer | Q50066861 |
| | Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. | Q52021616 |
| | The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency. | Q52312695 |
| | HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. | Q52680785 |
| | BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1. | Q52687695 |
| | Maraviroc is associated with latent HIV-1 reactivation through NF-κB activation in resting CD4+ T cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. | Q52695029 |
| | Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. | Q52731001 |
| | Novel Latency Reversal Agents for HIV-1 Cure. | Q52816327 |
| | CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. | Q53551795 |
| | CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. | Q53822439 |
| | Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. | Q54057499 |
| | CD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA. | Q54204987 |
| | Targeting the Latent Reservoir for HIV-1. | Q54210140 |
| | Seminal Simian Immunodeficiency Virus in Chronically Infected Cynomolgus Macaques Is Dominated by Virus Originating from Multiple Genital Organs. | Q54222581 |
| | Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T Cells. | Q54224088 |
| | Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells. | Q54228206 |
| | Reduction in terminally differentiated T cells in virologically controlled HIV-infected aging patients on long-term antiretroviral therapy. | Q55281020 |
| | Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. | Q55455666 |
| | The RNA surveillance proteins UPF1, UPF2 and SMG6 affect HIV-1 reactivation at a post-transcriptional level. | Q55514032 |
| | HIV-1 DNA load analysis in peripheral blood lymphocytes and monocytes from naïve and HAART-treated individuals | Q56993481 |
| | Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency | Q57044843 |
| | Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection | Q57053202 |
| | Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection | Q57072848 |
| | Greater diversity of HIV DNA variants in the rectum compared to variants in the blood in patients without HAART | Q57095890 |
| | Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation | Q57164880 |
| | Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy | Q57176735 |
| | Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals | Q57201701 |
| | Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4 T Cells Harboring Reactivated Human Immunodeficiency Virus | Q57565007 |
| | Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency | Q58003757 |
| | Metagenomic sequencing of HIV-1 in the blood and female genital tract reveals little quasispecies diversity during acute infection | Q58089557 |
| | Sex-Based Differences in HIV-1 Reservoir Activity and Residual Immune Activation | Q58104425 |
| | BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. | Q36198250 |
| | Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells | Q36228932 |
| | Early Antiretroviral Therapy Is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations | Q36238501 |
| | Immunological biomarkers predict HIV-1 viral rebound after treatment interruption | Q36250043 |
| | LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes | Q36286785 |
| | Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein | Q36332978 |
| | Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation | Q36409885 |
| | In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors | Q36523946 |
| | Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. | Q36525896 |
| | Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production | Q36547664 |
| | HIV latency: experimental systems and molecular models. | Q36585019 |
| | In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. | Q36592182 |
| | Development of 5' LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals | Q36596027 |
| | Germinal Center T Follicular Helper Cells Are Highly Permissive to HIV-1 and Alter Their Phenotype during Virus Replication | Q36655850 |
| | Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy. | Q36736667 |
| | HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression | Q36781531 |
| | The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb | Q36790027 |
| | CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression | Q36846285 |
| | HIV-1 transcription and latency: an update | Q36976156 |
| | Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation | Q37010047 |
| | The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication | Q37034469 |
| | LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV | Q37035177 |
| | Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling | Q37041173 |
| | CTIP2 is a negative regulator of P-TEFb | Q37068686 |
| | Defining HIV and SIV Reservoirs in Lymphoid Tissues. | Q37090999 |
| | High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. | Q37123276 |
| | The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function | Q37144949 |
| | HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study | Q37180359 |
| | The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence | Q37187497 |
| | Defective proviruses rapidly accumulate during acute HIV-1 infection | Q37239064 |
| | Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors | Q37257484 |
| | Broad activation of latent HIV-1 in vivo | Q37260309 |
| | Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation | Q37305160 |
| | Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy | Q37354047 |
| | Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency | Q28728736 |
| | HIV-1 integration in the human genome favors active genes and local hotspots | Q29618457 |
| | HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation | Q29619611 |
| | Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 |
| | A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. | Q30385378 |
| | Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection | Q30400191 |
| | HIV-1 Recruits UPF1 but Excludes UPF2 to Promote Nucleocytoplasmic Export of the Genomic RNA. | Q30488459 |
| | Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations | Q30490742 |
| | Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro | Q30558754 |
| | HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription | Q30835037 |
| | Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity | Q33220546 |
| | Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells | Q33250088 |
| | HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR | Q33292464 |
| | Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy | Q33373073 |
| | Control of stochastic gene expression by host factors at the HIV promoter | Q33398516 |
| | miR-198 inhibits HIV-1 gene expression and replication in monocytes and its mechanism of action appears to involve repression of cyclin T1 | Q33400321 |
| | Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection | Q33476165 |
| | CpG methylation controls reactivation of HIV from latency | Q33495565 |
| | Negative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat | Q33602605 |
| | Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. | Q33717839 |
| | An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription | Q33724213 |
| | The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1 | Q33725916 |
| | Vaginal myeloid dendritic cells transmit founder HIV-1. | Q33744037 |
| | Epigenetic analysis of HIV-1 proviral genomes from infected individuals: predominance of unmethylated CpG's. | Q33768729 |
| | Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. | Q33771155 |
| | Human immunodeficiency virus type 1 populations in blood and semen | Q33782102 |
| | HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications | Q33805298 |
| | High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay | Q33817708 |
| | Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. | Q33838633 |
| | Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy | Q33843388 |
| | Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. | Q33883423 |
| | The Human Immunodeficiency Virus 1 ASP RNA promotes viral latency by recruiting the Polycomb Repressor Complex 2 and promoting nucleosome assembly | Q33893725 |
| | Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. | Q34057748 |
| | Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors | Q34059119 |
| | Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog | Q34284559 |
| | Evidence that CD32a does not mark the HIV-1 latent reservoir. | Q59076591 |
| | Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3 | Q59132651 |
| | Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma | Q59151109 |
| | Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir | Q59355676 |
| | HIV-1 latent reservoir size and diversity are stable following brief treatment interruption | Q59358567 |
| | Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency | Q59805107 |
| | Procyanidin trimer C1 reactivates latent HIV as a triple combination therapy with kansui and JQ1 | Q59811612 |
| | HIV-1 infection increases microRNAs that inhibit Dicer1, HRB and HIV-EP2, thereby reducing viral replication | Q61809755 |
| | Insight in HIV Integration Site Selection Provides a Block-and-Lock Strategy for a Functional Cure of HIV Infection | Q61813266 |
| | Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals | Q63727608 |
| | Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption | Q63728944 |
| | Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection | Q64097650 |
| | Persistent Viral Reservoirs in Lymphoid Tissues in SIV-Infected Rhesus Macaques of Chinese-Origin on Suppressive Antiretroviral Therapy | Q64253365 |
| | Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection | Q74111073 |
| | Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues | Q78678650 |
| | Longitudinal and cross-sectional studies of HIV-1 RNA and DNA loads in blood and the female genital tract | Q80997535 |
| | Lower genitourinary tract sources of seminal HIV | Q83230103 |
| | Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients | Q84066778 |
| | Persistent HIV RNA shedding in semen despite effective antiretroviral therapy | Q84473924 |
| | Using Barcoded HIV Ensembles (B-HIVE) for Single Provirus Transcriptomics | Q88931790 |
| | Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1 | Q90035728 |
| | HIV-1 Vpr mediates the depletion of the cellular repressor CTIP2 to counteract viral gene silencing | Q90069375 |
| | Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells | Q90440611 |
| | Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy | Q90616753 |
| | The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like | Q90733079 |
| | Hematopoietic Stem and Progenitor Cells Are a Distinct HIV Reservoir that Contributes to Persistent Viremia in Suppressed Patients | Q90776929 |
| | Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa | Q90811783 |
| | Apobec3A maintains HIV-1 latency through recruitment of epigenetic silencing machinery to the long terminal repeat | Q91168113 |
| | Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation | Q91176634 |
| | Microglial Cells: The Main HIV-1 Reservoir in the Brain | Q91219472 |
| | Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy | Q91247946 |
| | A quantitative approach for measuring the reservoir of latent HIV-1 proviruses | Q91284113 |
| | HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy | Q91341307 |
| | Naive CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1 | Q91501278 |
| | Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription | Q91563978 |
| | Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments | Q91618889 |
| | Premature aging of T cells is associated with faster HIV-1 disease progression | Q37399302 |
| | Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study | Q37413059 |
| | Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency | Q37419972 |
| | The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. | Q37428017 |
| | Characterization of Cdk9 T-loop phosphorylation in resting and activated CD4(+) T lymphocytes. | Q37429329 |
| | HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy | Q37461290 |
| | Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing | Q37489352 |
| | The kidney as a reservoir for HIV-1 after renal transplantation | Q37524140 |
| | Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues | Q37587740 |
| | A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy | Q37604524 |
| | Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies | Q37644561 |
| | HIV-1 persistence in CD4+ T cells with stem cell-like properties | Q37646541 |
| | Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency | Q37695602 |
| | Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection | Q37726311 |
| | HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters | Q37734357 |
| | The lungs as anatomical reservoirs of HIV infection | Q38154849 |
| | HIV-1 latency in monocytes/macrophages | Q38206643 |
| | Characterization of the HIV-1 RNA associated proteome identifies Matrin 3 as a nuclear cofactor of Rev function | Q38257666 |
| | Landscape review of current HIV 'kick and kill' cure research - some kicking, not enough killing. | Q38636019 |
| | CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo. | Q38667923 |
| | Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV. | Q38727211 |
| | Hyperactivation of HUSH complex function by Charcot-Marie-Tooth disease mutation in MORC2. | Q38743878 |
| | A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4+ T-cells | Q38795594 |
| | HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter | Q38810619 |
| | Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial | Q38958099 |
| | Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy | Q38971085 |
| | Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV. | Q39023875 |
| | Position effects influence HIV latency reversal | Q39167914 |
| | Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation | Q39173734 |
| | Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir | Q39276828 |
| | Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial | Q39361321 |
| | Transcription regulation through promoter-proximal pausing of RNA polymerase II. | Q39442921 |
| | TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-α. | Q39585002 |
| | Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter. | Q39723092 |
| | Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy | Q34290545 |
| | Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies | Q34349201 |
| | Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein | Q34381967 |
| | CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells | Q34395160 |
| | Transcriptional interference antagonizes proviral gene expression to promote HIV latency | Q34443670 |
| | Nuclear architecture dictates HIV-1 integration site selection. | Q34465264 |
| | A cytoplasmic RNA virus generates functional viral small RNAs and regulates viral IRES activity in mammalian cells | Q34489762 |
| | Persistence of infectious HIV on follicular dendritic cells | Q34512487 |
| | Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy | Q34588169 |
| | Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes | Q34695803 |
| | Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages | Q34869340 |
| | HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients | Q34922069 |
| | HIV-1 Nef sequence and functional compartmentalization in the gut is not due to differential cytotoxic T lymphocyte selective pressure | Q34995124 |
| | Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments | Q35043695 |
| | Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection | Q35064033 |
| | Recent observations on HIV type-1 infection in the genital tract of men and women | Q35071029 |
| | The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy | Q35076758 |
| | Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation | Q35077057 |
| | Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders | Q35154529 |
| | Dynamics of HIV latency and reactivation in a primary CD4+ T cell model | Q35176166 |
| | Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption | Q35190018 |
| | Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. | Q35192959 |
| | Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts | Q35202038 |
| | Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection | Q35219829 |
| | Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. | Q35318746 |
| | Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations | Q35521811 |
| | HIV envelope-mediated, CCR5/α4β7-dependent killing of CD4-negative γδ T cells which are lost during progression to AIDS | Q35585948 |
| | HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells. | Q35661660 |
| | Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. | Q35720063 |
| | Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. | Q35729054 |
| | The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo | Q35778783 |
| | Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma | Q35822484 |
| | Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. | Q35845347 |
| | Follicular Dendritic Cells Retain Infectious HIV in Cycling Endosomes | Q35856793 |
| | H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells | Q35914266 |
| | Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy | Q35943698 |
| | Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy | Q35965172 |
| | Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation | Q36037844 |
| | Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients | Q36076018 |
| | CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. | Q36077348 |
| | Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals | Q36108518 |
| | Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. | Q40070005 |
| | The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity | Q40130732 |
| | A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. | Q40150438 |
| | Crosstalk between histone modifications indicates that inhibition of arginine methyltransferase CARM1 activity reverses HIV latency. | Q40150928 |
| | Suppression of microRNA-silencing pathway by HIV-1 during virus replication | Q40166750 |
| | Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1. | Q40181655 |
| | Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. | Q40192992 |
| | SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency | Q40205664 |
| | HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy | Q40240401 |
| | Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab | Q40275173 |
| | CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses | Q40290840 |
| | A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells | Q40336664 |
| | Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents | Q40375858 |
| | Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. | Q40391119 |
| | Exploring the anatomical HIV reservoirs: role of the testicular tissue | Q40484243 |
| | Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression | Q40507650 |
| | HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function | Q40515496 |
| | Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults | Q40525821 |
| | PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals | Q40653907 |
| | Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes | Q40886843 |
| | Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system | Q40889762 |
| | Long-term nonprogressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy | Q41167388 |
| | GENE SILENCING. Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells. | Q41529408 |
| | Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency | Q41730261 |
| | Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. | Q41880147 |
| | Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation | Q41885967 |
| | Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs. | Q41936227 |
| | Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection | Q41978842 |
| | Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. | Q42052356 |
| | Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency | Q42100247 |
| | NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation | Q42128724 |
| | Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with immune activation markers | Q42243907 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | heterogeneity | Q928498 |
| P304 | page(s) | 3060 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Frontiers in Microbiology | Q27723481 |
| P1476 | title | Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs | |
| P478 | volume | 10 | |